These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29098395)

  • 1. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
    Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
    Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
    Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells.
    Iwamoto Y; Ishii K; Kanda H; Kato M; Miki M; Kajiwara S; Arima K; Shiraishi T; Sugimura Y
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):933-939. PubMed ID: 28243746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
    Hori Y; Ishii K; Kanda H; Iwamoto Y; Nishikawa K; Soga N; Kise H; Arima K; Sugimura Y
    Cancer Prev Res (Phila); 2011 Jan; 4(1):87-96. PubMed ID: 21205739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
    Mimeault M; Rachagani S; Muniyan S; Seshacharyulu P; Johansson SL; Datta K; Lin MF; Batra SK
    Oncotarget; 2015 Feb; 6(6):3887-903. PubMed ID: 25682877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
    Eskra JN; Schlicht MJ; Bosland MC
    Prostate; 2019 Feb; 79(2):223-233. PubMed ID: 30345530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
    Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
    Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
    Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
    Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-assembled albumin nanoparticles for combination therapy in prostate cancer.
    Lian H; Wu J; Hu Y; Guo H
    Int J Nanomedicine; 2017; 12():7777-7787. PubMed ID: 29123392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
    Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
    Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
    Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
    Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H
    Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines.
    Karaca B; Degirmenci M; Ozveren A; Atmaca H; Bozkurt E; Karabulut B; Sanli UA; Uslu R
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1273-80. PubMed ID: 25925002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells.
    Nakamura A; Matsunaga W; Gotoh A
    Anticancer Res; 2018 Feb; 38(2):803-809. PubMed ID: 29374705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective photothermal chemotherapy with docetaxel-loaded gold nanospheres in advanced prostate cancer.
    Shen Y; Ma Z; Chen F; Dong Q; Hu Q; Bai L; Chen J
    J Drug Target; 2015; 23(6):568-76. PubMed ID: 25738990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
    Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
    Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo.
    Jorfi S; Ansa-Addo EA; Kholia S; Stratton D; Valley S; Lange S; Inal J
    Sci Rep; 2015 Aug; 5():13006. PubMed ID: 26302712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.